Seizures and myoclonus associated with antidepressant treatment: Assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors

Acta Psychiatrica Scandinavica

Volumn 96, Issue 5, 1997, Pages 379-384

  Spigset, O ^a   Hedenmalm, K ^a   Dahl, M L ^b   Wiholm, B E ^c   Dahlqvist, R ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Adverse drug reactions; Antidepressants; Cytochromes P 450; Myoclonus; Predisposing factors; Seizures

Indexed keywords

ALIMEMAZINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DEXTROPROPOXYPHENE; DIXYRAZINE; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; LOFEPRAMINE; MAPROTILINE; MELPERONE; MIANSERIN; NEUROLEPTIC AGENT; NORFLOXACIN; PAROXETINE; PROPIOMAZINE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DISEASE PREDISPOSITION; DRUG METABOLISM; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; MYOCLONUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEIZURE;

EID: 0030659112     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb09933.x     Document Type: Article

References (33)

1. MENDEZ MF. Epilepsy: psychiatric aspects and use of psychotropics. Psychosomatics 1984: 25: 883-894.
2. SKOWRON DM, STIMMEL GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992: 12: 18-22.
3. SCHAUL N, DEGREFF G, NEY GC. Psychotropic drugs and seizures. In: KANE JM, LIEBERMAN JA, ed. Adverse effects of psychotropic drugs. New York: The Guilford Press, 1992: 321-337.
4. TOONE BK, FENTON GW. Epileptic seizures induced by psychotropic drugs. Psychol Med 1977: 7: 265-270.
5. LEJOYEUX M, ROUILLON F, ADÉS J, GORWOOD P. Neural symptoms induced by tricyclic antidepressants: phenomenology and pathophysiology. Acta Psychiatr Scand 1992: 85: 249-256.
6. NOBLE J, MATTHEW H. Acute poisoning by tricyclic antidepressants: clinical features and management of 100 patients. Clin Toxicology 1969: 2: 403-421.
7. HERMAN I, ZALMA A, DURAND C, GREEN AI. Clozapine-induced myoclonic jerks and drop attacks. J Clin Psychiatry 1992: 53: 329-330.
8. HALLER E, BINDER RL. Clozapine and seizures. Am J Psychiatry 1990: 147: 1069-1071.
9. BERTILSSON L, DAHL M-L. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996: 3: 200-223.
10. ALVAN G, BECHTEL P, ISELIUS L, GUNDERT-REMY U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacology 1990: 39: 533-537.
11. bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988: 27: 5447-5454.
12. STEINER E, ISELIUS L, ALVÁN G, LINDSTEN J, SJÖQVIST F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 1985: 38: 394-401.
13. DAHL M-L, JOHANSSON I, PALMERTZ MP, INGELMAN-SUNDBERG M, SJÖQVIST F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992: 51: 12-17.
14. WILKINSON GR, GUENGERICH FP, BRANCH RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: KALOW W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 657-685.
15. GOLDSTEIN JA, FALETTO MB, ROMKES-SPARKS M et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994: 33: 1743-1752.
16. DEMORAIS SMF, WILKINSON GR, BLAISDELL J, NAKAMURA K, MEYER UA, GOLDSTEIN JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994: 269: 15419-15422.
17. DEMORAIS SMF, WILKINSON GR, BLAIDSELL J, MAYER UA, NAKAMURA K, GOLDSTEIN JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacology 1994: 46: 594-598.
18. HEIM M, MEYER UA. Genotyping of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336: 529-532.
19. CHANG M, DAHL M-L, TYBRING G, GÖTHARSON E, BERTILSSON L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995: 5: 358-363.
20. ZACCARA G, MUSCAS GC, MESSORI A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Safety 1990: 5: 109-151.
21. WIHOLM B-E, OLSSON S, MOORE N, WOOD S. Spontaneous reporting systems outside the United States. In: STROM BL, ed. Pharmacoepidemiology, 2nd edn. Chichester: John Wiley & Sons, 1994: 139-155.
22. DUKES MNG. The importance of adverse drug reactions in drug regulation. Drug Safety 1990: 5: 3-6.
23. JICK H, DINAN BJ, HUNTER JR et al. Tricyclic antidepressants and convulsions. J Clin Psychopharmacology 1983: 3: 182-185.
24. STEINER E, BERTILSSON L, SAVE J, BERTLING I, SJÖQVIST F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988: 44: 431-435.
25. SPINA E, ANCIONE M, Di ROSA AE, MEDURI M, CAPUTI AP. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacology 1992: 42: 347-348.
26. ARTHUR H, DAHL M-L, SIWERS B, SJÖQVIST F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacology 1995: 15: 211-216.
27. SPINA E, STURIALE V, VALVO S et al. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. Acta Psychiatr Scand 1992: 86: 364-366.
28. PECK AW, STERN WC, WATKINSON C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983: 44: 197-201.
29. DEVEAUGH-GEISS J, LANDAU P, KATZ R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 1989: 25: 36-40.
30. PRESKORN SH, FAST GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992: 53: 160-162.
31. SMITH M, ANGRISI B, COOPER T. Seizures associated with a high plasma maprotiline level. J Clin Psychopharmacology 1983: 3: 57-58.
32. MOLNAR G. Seizures associated with high maprotiline serum concentrations. Can J Psychiatry 1983: 28: 555-556.
33. LLERENA A, HERRAIZ AG, COBALEDA J, JOHANSSON I, DAHL, M-L. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993: 54: 606-611.